Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) and 8X8 (NASDAQ:EGHT – Get Free Report) are both small-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.
Risk & Volatility
Coeptis Therapeutics has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500. Comparatively, 8X8 has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
Institutional and Insider Ownership
13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 94.0% of 8X8 shares are owned by institutional investors. 24.2% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 2.1% of 8X8 shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Coeptis Therapeutics and 8X8’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coeptis Therapeutics | -773.72% | -49.45% | -46.88% |
| 8X8 | 0.64% | 28.72% | 6.14% |
Earnings and Valuation
This table compares Coeptis Therapeutics and 8X8″s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coeptis Therapeutics | N/A | N/A | -$11.92 million | ($1.63) | -2.49 |
| 8X8 | $735.75 million | 0.40 | $1.65 million | $0.04 | 51.38 |
8X8 has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than 8X8, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings for Coeptis Therapeutics and 8X8, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coeptis Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| 8X8 | 1 | 1 | 2 | 0 | 2.25 |
8X8 has a consensus price target of $3.12, suggesting a potential upside of 52.07%. Given 8X8’s stronger consensus rating and higher possible upside, analysts plainly believe 8X8 is more favorable than Coeptis Therapeutics.
Summary
8X8 beats Coeptis Therapeutics on 12 of the 13 factors compared between the two stocks.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
About 8X8
8×8, Inc. engages in the provision of enterprise communication solutions. It offers solutions to the business services, education, financial services, government, healthcare, and manufacturing industries. The company was founded in February 1987 and is headquartered in Campbell, CA.
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
